natgillin/translations-raw huggingface dataset:
Rebif should be initiated with caution in patients with a history of significant liver disease, clinical evidence of active liver disease, alcohol abuse or increased serum ALT (>2.5 times ULN).
Zdravljenje z zdravilom Rebif moramo uvajati previdno pri bolnikih s pomembnimi jetrnimi boleznimi v anamnezi, s klinično potrjeno aktivno jetrno boleznijo, zlorabo alkohola ali zvišano serumsko ravnjo ALT (>2,5-kratna ULN).
Nephrotic syndrome*, glomerulosclerosis* (see section 4.4) General disorders and administration site conditions Very common:
nefrotski sindrom*, glomeruloskleroza* (glejte poglavje 4.4) Splošne težave in spremembe na mestu aplikacije Zelo pogosti:
Caution should be exercised when administering Rebif in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance, e.g. antiepileptics and some classes of antidepressants.
Previdnost se zahteva pri uporabi zdravila Rebif v kombinaciji z zdravili, ki imajo ozek terapevtski indeks in se v glavnem razgrajujejo preko jetrnega citokrom P450 sistema, npr. antiepileptiki in nekatere vrste antidepresivov.
Cessation of therapy with Rebif should be considered (see sections 4.3 and 4.8).
Proučiti moramo možnost prenehanja zdravljenja z zdravilom Rebif (glejte poglavji 4.3 in 4.8).
To minimise the risk of injection site necrosis patients should be advised to:
Za zmanjševanje tveganja nastanka nekroz na mestu injiciranja, moramo bolnikom svetovati, da:
The overall incidence of these is slightly higher with Rebif 44 than Rebif 22 micrograms.
Celokupna incidenca le-teh je nekoliko višja pri zdravilu Rebif 44 mikrogramov kot pri zdravilu Rebif 22 mikrogramov.
Only sparse safety and efficacy data are available from non-ambulatory patients with multiple sclerosis.
Podatki o varnosti in učinkovitosti pri neambulantnih bolnikih z multiplo sklerozo so omejeni.
• Resting your wrist on the skin near the site, stick the needle at a right angle straight into the skin with a quick, firm motion.
• Z zapestjem naslonjenim na kožo v bližini mesta, s hitrim in trdnim gibom zabodite iglo pod pravim kotom naravnost v kožo.
Prior to injection and for an additional 24 hours after each injection, an antipyretic analgesic is advised to decrease flu-like symptoms associated with Rebif administration.
Pred injiciranjem in še naslednjih 24 ur po vsaki injekciji je priporočena uporaba antipiretičnega analgetika za zmanjševanje gripi podobnih simptomov, povezanih z uporabo zdravila Rebif.
• Blood clots in the small blood vessels that can affect your kidneys (thrombotic thrombocytopenic purpura or haemolytic uremic syndrome).
• Krvni strdki v majhnih krvnih žilah, ki lahko vplivajo na delovanje ledvic (trombotična trombocitopenična purpura ali hemolitično-uremični sindrom).
These reactions are rare (may affect up to 1 in 1,000 people).
Te reakcije so redke (pojavijo se lahko pri največ 1 od 1.000 bolnikov).
• Inject the medicine by using a slow, steady push (push the plunger all the way in until the syringe is empty).
• S počasnim in enakomernim pritiskom vbrizgajte zdravilo (potiskajte bat do konca, dokler injekcijska brizga ni prazna).
If, immediately following Rebif administration you experience a sudden difficulty breathing, which may appear in association with swelling of face, lips, tongue or throat, nettle rash, itching all over the body, and a feeling of weakness or faintness, contact your doctor immediately or seek urgent medical attention.
Če takoj po dajanju zdravila Rebif začutite nenadne težave z dihanjem, ki se lahko pojavijo skupaj z otekanjem obraza, ustnic, jezika ali žrela, koprivnico, srbenjem po celem telesu in z občutkom šibkosti ali omedlevice, se takoj posvetujte s svojim zdravnikom ali poiščite nujno zdravniško pomoč.
Mean CUA Lesions per Subject per Scan During the Double Blind Period Least Square Means (SE) * tiw - three times per week
Srednje lezije CUA na osebo in na slikanje v dvojno slepem obdobju Srednja vrednost po metodi najmanjših kvadratov (SE) * tiw - trikrat na teden
• Epileptic seizures
• epileptični napadi
Patients with cardiac disease, such as angina, congestive heart failure or arrhythmia, should be closely monitored for worsening of their clinical condition during initiation of therapy with interferon beta-1a.
Bolnike s srčnimi boleznimi, kot so angina pektoris, kongestivno srčno popuščanje ali aritmija, moramo skrbno spremljati na poslabšanje njihove klinične slike med uvajanjem zdravljenja z interferonom beta-1a.
Possible symptoms resulting from these changes could include tiredness, reduced ability to fight infection, bruising or unexplained bleeding.
Možni znaki, ki se lahko pojavijo kot posledica teh sprememb, so utrujenost, zmanjšana odpornost na okužbe, podplutbe ali nepojasnjene krvavitve.
In case of severe or persistent undesirable effects, the dose of Rebif may be temporarily lowered or interrupted, at the discretion of the physician.
V primeru hudih ali vztrajnih neželenih učinkov, se lahko po presoji zdravnika, odmerek zdravila Rebif začasno zmanjša ali ukine.
The patients enrolled into the trial had at least two clinically silent lesions on the T2-weighted MRI scan, with a size of at least 3 mm, at least one of which is ovoid or periventricular or infratentorial.
Bolniki, vključeni v preskušanje, so imeli vsaj dve klinično tihi leziji na s T2 uteženem magnetno-resonančnem slikanju velikosti vsaj 3 mm, od katerih je vsaj ena ovoidna ali periventrikularna ali infratentorialna.
Time to peak concentrations following a single subcutaneous injection were 24 to 48 hours for neopterin, beta-2-microglobulin and 2'5'OAS, 12 hours for MX1 and 24 hours for OAS1 and OAS2 gene expression.
Čas do največje koncentracije po eni subkutani injekciji je bil 24 do 48 ur za neopterin, beta-2-mikroglobulin in 2'5'OAS, 12 ur za MX1 in 24 ur za izraženost gena OAS1 in OAS2.
You should not stop or alter the medication without your doctor's advice.
Zdravljenja ne smete prekiniti ali spreminjati, ne da bi se predhodno posvetovali s svojim zdravnikom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 04 May 1998
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 04. maj 1998 Datum zadnjega podaljšanja: 04. maj 2008
Anaphylactic reactions*
anafilaktične reakcije*
It may cause toxic reactions and allergic reactions in infants and children up to 3 years old.
Lahko povzroči toksične reakcije in alergijske reakcije pri dojenčkih in otrocih do 3. leta starosti.
Use in children and teenagers (2 to 17 years old) No formal clinical studies have been conducted in children or teenagers.
Uporaba pri otrocih in mladostnikih (starih 2 do 17 let) Formalnih kliničnih preskušanj pri otrocih ali mladostnikih niso izvedli.
Patients exhibiting depression should be monitored closely during therapy with Rebif and treated appropriately.
Bolnike, ki kažejo znake depresije, moramo med zdravljenjem z zdravilom Rebif skrbno nadzorovati in jih ustrezno zdraviti.
These changes in the thyroid activity are almost always not felt by the patient as symptoms; however your doctor may recommend testing as appropriate.
Simptomov, ki kažejo na spremembe aktivnosti ščitnice, bolniki skoraj nikoli ne opazijo, zdravnik pa lahko svetuje ustrezna testiranja.
Injection site inflammation, injection site reaction, influenza-like symptoms
vnetje na mestu injiciranja, reakcija na mestu injiciranja, gripi podobni simptomi
Central nervous system-related adverse events associated with the use of interferon beta (e.g. dizziness) might influence the patient's ability to drive or use machines (see section 4.8).
Neželeni dogodki v povezavi z uporabo interferona beta, vezani na osrednji živčni sistem (npr. omotica), lahko vplivajo na bolnikovo sposobnost za vožnjo ali upravljanje strojev (glejte poglavje 4.8).
• Hold RebiSlide in place until “0” appears in the dose window, then wait 10 seconds before removing the needle from the skin.
• Držite pripomoček RebiSlide na mestu dokler se v oknu za odmerek ne prikaže »0«, nato počakajte 10 sekund, preden odstranite iglo iz kože.
If you get some or all of these symptoms: - foamy urine - fatigue - swelling, particularly in the ankles and eyelids, and weight gain.
Če se pojavijo nekateri ali vsi od teh simptomov: - penjenje urina, - utrujenost, - oteklina, zlasti gležnjev in vek, ter povečanje telesne mase.
Rebif must then be returned to the refrigerator and used before the expiry date.
Nato mora zdravilo Rebif postaviti nazaj v hladilnik in ga uporabiti do datuma izteka roka uporabnosti.
If the patient population was divided into 2 subgroups (those with and those without relapses in the 2-year period prior to study entry), there was no effect on disability in patients without relapses, but in patients with relapses, the proportion with progression in disability at the end of the study was reduced from 70% (placebo) to 57% (Rebif 22 micrograms and 44 micrograms combined).
Če so razdelili populacijo bolnikov v dve podskupini (na bolnike z in brez pojava zagonov v 2 letih pred vključitvijo v študijo), ni bilo pomembnega učinka na razvoj nesposobnosti pri bolnikih brez zagonov, vendar pa se je pri bolnikih z zagoni delež tistih z napredovalo nesposobnostjo na koncu študije zmanjšal iz 70 % (placebo) na 57 % (zdravilo Rebif 22 mikrogramov v kombinaciji z zdravilom Rebif 44 mikrogramov).
• Inflammation of the fatty tissue under the skin (panniculitis), which can make the skin feel hard and possibly develop painful red lumps or patches.
• vnetje maščobnega tkiva pod kožo (panikulitis), zaradi česar se lahko pojavi občutek otrdele kože, lahko pa se razvijejo tudi boleče rdeče bule ali lise.
Rebif should be administered with caution to patients with previous or current depressive disorders in particular to those with antecedents of suicidal ideation (see section 4.3).
Zdravilo Rebif moramo uporabljati previdno pri bolnikih, ki so imeli ali imajo trenutno depresivne bolezni, zlasti pri tistih s predhodnimi samomorilnimi mislimi (glejte poglavje 4.3).
Safety and efficacy with Rebif have not been demonstrated beyond 4 years of treatment.
Varnost in učinkovitost zdravljenja z zdravilom Rebif, ki traja več kot štiri leta, nista dokazani.
• Irregularities and/or changes in menstrual flow
• nerednem in/ali spremenjenem menstruacijskem ciklusu
The precise incidence of antibodies is as yet uncertain.
Natančna incidenca pojava protiteles še ni znana.
• Liver inflammation (hepatitis)
• vnetje jeter (hepatitis)
Clinical studies indicate that multiple sclerosis patients can receive Rebif and corticosteroids or ACTH during relapses.
Klinične študije kažejo, da bolniki z multiplo sklerozo pri relapsu lahko prejemajo zdravilo Rebif skupaj s kortikosteroidi ali ACTH.
What Rebif is and what it is used for What you need to know before you use Rebif How to use Rebif
Kaj je zdravilo Rebif in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Rebif Kako uporabljati zdravilo Rebif Možni neželeni učinki
This medicine is for multidose use.
To zdravilo je za večkratno odmerjanje.
• The first injection(s) must be performed under the supervision of an appropriately qualified healthcare professional.
• Dajanje prve injekcije (injekcij) mora biti izvedeno pod nadzorom ustrezno usposobljene zdravstvene osebe.
Over 4 years, the reduction in the mean exacerbation rate was 22% in patients treated with Rebif 22 micrograms, and 29% in patients treated with Rebif 44 micrograms group compared with a group of patients treated with placebo for 2 years and then either Rebif 22 or Rebif 44 micrograms for 2 years.
Tekom 4 let se je povprečna pogostnost zagonov zmanjšala za 22 % pri bolnikih, ki so prejemali zdravilo Rebif 22 mikrogramov, in za 29 % pri bolnikih, ki so prejemali zdravilo Rebif 44 mikrogramov, v primerjavi s skupino bolnikov, ki so 2 leti prejemali placebo in nato še 2 leti zdravilo Rebif 22 mikrogramov ali zdravilo Rebif 44 mikrogramov.
If you are uncertain about the benefits, please consult your doctor.
Če niste prepričani o koristih, se posvetujte z zdravnikom.
Rebif is available in three strengths: 8.8 micrograms, 22 micrograms and 44 micrograms.
Zdravilo Rebif je na voljo v treh jakostih: 8,8 mikrogramov, 22 mikrogramov in 44 mikrogramov.
Rebif has not yet been investigated in patients with primary progressive multiple sclerosis, and should not be used in these patients.
Zdravilo Rebif še ni bilo raziskano pri bolnikih s primarno progresivno multiplo sklerozo, zato se ga pri teh bolnikih ne sme uporabljati.
During the injection, the button will flash with a green light.
Med injiciranjem gumb utripa z zeleno lučko.
Prompt treatment of nephrotic syndrome is required and discontinuation of treatment with Rebif should be considered.
V primeru nefrotskega sindroma je potrebno takojšnje zdravljenje; razmisliti pa je treba tudi o prenehanju zdravljenja z zdravilom Rebif.
Rebif contains benzyl alcohol
Zdravilo Rebif vsebuje benzilalkohol
Metabolism Interferon beta-1a is mainly metabolised and excreted by the liver and the kidneys.
Presnova Interferon beta-1a se v glavnem presnavlja in izloča skozi jetra in ledvice.
From the fifth week onwards, after you have completed your initiation period, you will follow the usual dose regimen.
Od petega tedna naprej, ko boste zaključili uvajalno obdobje, boste sledili običajnemu režimu odmerjanja.
These should be more frequent when initiating Rebif 44 micrograms.
Testi morajo biti pogostejši pri uvajanju zdravljenja z zdravilom Rebif 44 mikrogramov.
• NOTE: From the fifth week onwards, after you have completed your initiation period, 0.5 mL (corresponding to the usual dose) should be selected in the dose window of the device.
• OPOMBA: Od petega tedna naprej, ko končate začetno obdobje, izberite v oknu za odmerek pripomočka 0,5 ml (kar ustreza običajnemu odmerku).
th week
- 2. teden
• Flu-like symptoms, such as headache, fever, chills, muscle and joint pains, fatigue and nausea are very common (may affect more than 1 in 10 people).
• Gripi podobni simptomi, kot so glavobol, zvišana telesna temperatura, mrzlica, bolečine v mišicah in sklepih, utrujenost in siljenje na bruhanje, so zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov).
The administration of interferons has been associated with anorexia, dizziness, anxiety, arrhythmias, vasodilation and palpitation, menorrhagia and metrorrhagia.
Uporabo interferonov povezujejo z anoreksijo, omotico, anksioznostjo, aritmijami, vazodilatacijo in palpitacijo, menoragijo in metroragijo.
• Injection site reactions including redness, swelling, discoloration, inflammation, pain and skin breakdown are very common.
• Reakcije na mestu injiciranja, vključno z rdečico, oteklino, obarvanostjo kože, vnetjem, bolečino in razpokanjem kože, so zelo pogoste.
• When you do this please read carefully and follow the “RebiDose Instructions for Use” provided separately in the booklet.
• Ko ste to storili, natančno preberite in upoštevajte » Navodila za uporabo peresnika RebiDose«, ki so priložena ločeno, v knjižici.
Rebif can be used during breastfeeding.
Zdravilo Rebif se lahko uporablja med dojenjem.
Blood and the lymphatic system disorders Very common:
Bolezni krvi in limfatičnega sistema Zelo pogosti:
Thyroid dysfunction, most often presenting as hypothyroidism or hyperthyroidism
motnje delovanja ščitnice, najpogosteje v obliki hipotireoidizma ali hipertireoidizma
Rebif is a highly purified soluble protein that is similar to the natural interferon beta that is produced in the human body.
Zdravilo Rebif je visoko prečiščena topna beljakovina, ki je podobna naravnemu interferonu beta, ki ga proizvaja človeško telo.
• Place RebiSmart at a right angle (90°) to the skin.
• Namestite RebiSmart pod pravim kotom (90°) na kožo.
These symptoms are usually mild, are more common at the start of the treatment and decrease with continued use.
Ti simptomi so običajno blagi in pogostejši na začetku zdravljenja, z nadaljnjo uporabo pa se zmanjšujejo.
It must not be given to premature babies or neonates.
Uporaba pri nedonošenčkih ali novorojenčkih ni dovoljena.
In clinical trials, this was characterised by two or more acute exacerbations in the previous two years (see section 5.1).
V kliničnih preskušanjih je bilo to opredeljeno z dvema ali več akutnimi zagoni bolezni v obdobju zadnjih dveh let (glejte poglavje 5.1).
The presence of antibodies has been shown to attenuate the pharmacodynamic response to interferon beta-1a (beta-2 microglobulin and neopterin).
Pokazalo se je, da prisotnost protiteles slabi farmakodinamični odziv na interferon beta-1a (beta-2 mikroglobulin in neopterin).
Patients with poor vision should not use RebiSlide unless someone with good eyesight can provide support.
Slabovidni bolniki ne smejo uporabljati pripomočka RebiSlide, razen če jim pomaga oseba, ki nima težav z vidom.
Hold the syringe like a pencil or dart.
Injekcijsko brizgo primite kot svinčnik ali puščico.
If a second clinical demyelinating event occurred confirming definite multiple sclerosis, patients switched to the recommended posology of Rebif 44 micrograms three times per week in an open label manner, while maintaining blinding as to initial randomisation.
Če je še drugi klinični dogodek z demielinizacijo potrdil dokončno multiplo sklerozo, so začeli bolnika zdraviti s priporočenim odmerjanjem zdravila Rebif 44 mikrogramov trikrat na teden z odprto oznako, vendar ob ohranitvi zaslepitve kot na začetku randomizacije.
Your doctor will advise you on the possible injection sites (good sites include the upper thighs and the lower abdomen).
Vaš zdravnik vas bo podučil o možnih mestih za injiciranje (dobra mesta vključujejo zgornji del beder in spodnji del trebuha).
• Once you have finished your injection, immediately discard RebiDose.
• Ko ste končali z injiciranjem, takoj zavrzite peresnik RebiDose.
• Drug-induced lupus erythematosus: a side-effect of long-term use of Rebif.
• eritematozni lupus zaradi zdravila: neželeni učinek dolgotrajnega zdravljenja z zdravilom Rebif.
In a 3-year study in patients with secondary progressive multiple sclerosis (EDSS 3-6.5) with evidence of clinical progression in the preceding two years and who had not experienced relapses in the preceding 8 weeks, Rebif had no significant effect on progression of disability, but relapse rate was reduced by approximately 30%.
V 3 letni študiji z bolniki, ki imajo sekundarno progresivno multiplo sklerozo (EDSS 3 do 6,5) s potrjenim kliničnim napredovanjem bolezni v predhodnih dveh letih in brez zagonov v predhodnih osmih tednih, zdravilo Rebif ni imelo pomembnega učinka na napredovanje nesposobnosti, vendar pa je zmanjšalo delež zagonov bolezni za približno 30 %.
It will also instruct you when you need to change the cartridge.
Dal vam bo tudi navodila o tem, kako zamenjati vložek.
Severe renal or hepatic failure and severe myelosuppression
Hudo ledvično ali jetrno odpovedovanje in huda mielosupresija
If there are particles or other visible signs of deteriorations, do not use it and contact your doctor, nurse or pharmacist for assistance.
Če opazite delce ali druge vidne znake kvarjenja, ga ne uporabite in se po pomoč obrnite na svojega zdravnika, medicinsko sestro ali farmacevta.
Treatment with Rebif should be stopped if icterus or other clinical symptoms of liver dysfunction appear.
Zdravljenje z zdravilom Rebif moramo ukiniti, če se pojavi zlatenica ali drugi klinični znaki motenj v delovanju jeter.
Neutropenia, lymphopenia, leukopenia, thrombocytopenia, anaemia
nevtropenija, limfopenija, levkopenija, trombocitopenija, anemija
The safety and efficacy of Rebif has been evaluated in patients with relapsing-remitting multiple sclerosis at doses ranging from 11 to 44 micrograms (3-12 million IU), administered subcutaneously three times per week.
Varnost in učinkovitost zdravila Rebif je bila ocenjena pri bolnikih z recidivno-remitentno multiplo sklerozo, pri odmerkih v razponu od 11 do 44 mikrogramov (3-12 milijonov i.e.), podkožno trikrat na teden.
Tissue destruction (necrosis), abscess and mass at injection site are uncommon (may affect up to 1 in 100 people).
Razgradnja tkiva (nekroza), abscesi in bule se na mestu injiciranja pojavljajo občasno (pojavijo se lahko pri največ 1 od 100 bolnikov).
Thyroid function testing is recommended at baseline and if abnormal, every 6-12 months following initiation of therapy.
Preiskave delovanja ščitnice se priporoča na začetku zdravljenja in, če so rezultati abnormalni, vsakih 6 do 12 mesecev od začetka zdravljenja.
Rebif should be administered with caution to patients with a history of seizures, to those receiving treatment with anti-epileptics, particularly if their epilepsy is not adequately controlled with antiepileptics (see sections 4.5 and 4.8).
Zdravilo Rebif moramo uporabljati previdno pri bolnikih, ki so imeli v preteklosti epileptične napade, ter pri bolnikih, ki se zdravijo z antiepileptiki, zlasti pri tistih, kjer napadov ni bilo mogoče zadovoljivo kontrolirati z antiepileptiki (glejte poglavji 4.5 in 4.8).
Weeks 3-4
3. in 4. teden
Rebif is used for the treatment of multiple sclerosis.
Zdravilo Rebif se uporablja za zdravljenje multiple skleroze.
The highest incidence of adverse reactions associated with Rebif therapy is related to flu-like syndrome.
Največja incidenca neželenih učinkov v zvezi z zdravljenjem z zdravilom Rebif je povezana z gripi podobnimi simptomi.
Your doctor has prescribed you a lower dose of 22 micrograms (6 million IU) given three times per week.
Vaš zdravnik vam je predpisal nižji odmerek 22 mikrogramov (6 milijonov i.e.) trikrat na teden.
After the injection of Rebif with either RebiSmart or RebiSlide
Po injiciranju zdravila Rebif bodisi s pripomočkom Rebismart ali Rebislide
Patients should be informed of the most frequent adverse reactions associated with interferon beta administration, including symptoms of the flu-like syndrome (see section 4.8).
Bolnik mora biti seznanjen z najbolj pogostimi neželenimi učinki, povezanimi z uporabo interferona beta, vključno s simptomi gripi podobnega sindroma (glejte poglavje 4.8).
No information is available on the effects of the interferon beta-1a on male fertility.
Ni podatkov o učinku interferona beta-1a na moško plodnost.
•Talk to your doctor or pharmacist before taking Rebif if you have an allergy (hypersensitivity) to any other medicines.
• Pred začetkom uporabe zdravila Rebif se posvetujte z zdravnikom ali farmacevtom, če imate alergijo (ste preobčutljivi) na katero koli zdravilo.
If there is liquid left, not all of the medicine has been injected and you should consult your doctor or nurse for assistance.
Če vidite ostanek tekočine, to pomeni, da ni bila injicirana celotna količina zdravila, zato se po pomoč obrnite na svojega zdravnika ali medicinsko sestro.
Talk to your doctor if you experience any of the following side effects:
Posvetujte se z zdravnikom, če se pojavi kateri od teh neželenih učinkov:
The first injection(s) must be performed under the supervision of an appropriately qualified healthcare professional.
Dajanje prve injekcije (injekcij) mora biti izvedeno pod nadzorom ustrezno usposobljene zdravstvene osebe.
If you use more Rebif than you should In case of overdose, contact your doctor immediately.
Če ste uporabili večji odmerek zdravila Rebif, kot bi smeli V primeru prekoračenega odmerka se takoj posvetujte z zdravnikom.
• Before the injection, use an alcohol wipe to clean the skin at the injection site.
• Pred injiciranjem uporabite za čiščenje kože na mestu injiciranja alkoholno blazinico.
Symptoms of the flu-like syndrome associated with interferon beta-1a therapy may prove stressful to patients with cardiac conditions.
Znaki gripi podobnega sindroma, ki so povezani z zdravljenjem z interferonom beta-1a, lahko stresno vplivajo na srčne bolnike.
E. Main body F. Button
D. nalepka E. osrednji del F. gumb
The proportion of patients with disability progression, as defined by at least one point increase in EDSS confirmed three months later, was reduced from 39% (placebo) to 27% (Rebif 44 micrograms).
Odstotek bolnikov z napredovanjem nesposobnosti, definiranim kot povečanje za najmanj eno točko po EDSS, potrjenim po 3 mesecih, se je zmanjšal iz 39 % (placebo) na 27 % (zdravilo Rebif 44 mikrogramov).